Total Return chart GI Innovation, Inc.

Stocks

End-of-day quote Korea S.E. 2026-10-27			5-day change	1st Jan Change
7,030.00 ^KRW	-8.22%		-14.27%	-60.15%

04-23	GI Innovation Enters Melanoma First-Line Treatment Market with GI-102 Approval for Phase 2 Clinical Trial Direct Comparison with Keytruda	CI
03-20	GI Innovation And Johnson & Johnson Enter Clinical Supply Agreement For Prostate Cancer Combination Therapy	CI

"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.